Ocata Therapeutics (NASDAQ: OCAT) is one of 290 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Ocata Therapeutics to related businesses based on the strength of its profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.
This table compares Ocata Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ocata Therapeutics Competitors||-5,401.04%||-162.42%||-36.21%|
49.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent recommendations for Ocata Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ocata Therapeutics Competitors||1156||3499||12020||245||2.67|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.73%. Given Ocata Therapeutics’ peers higher possible upside, analysts clearly believe Ocata Therapeutics has less favorable growth aspects than its peers.
Earnings & Valuation
This table compares Ocata Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ocata Therapeutics Competitors||$290.27 million||$35.99 million||62.27|
Ocata Therapeutics’ peers have higher revenue and earnings than Ocata Therapeutics. Ocata Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Ocata Therapeutics peers beat Ocata Therapeutics on 6 of the 8 factors compared.
Ocata Therapeutics Company Profile
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company’s advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Receive News & Ratings for Ocata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.